SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT00752076

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Detection of Epithelial Growth Factor Receptor (EGFR) Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment

1. Detection EGFR mutation of cancer cells from malignant pleural effusion. 2. Established the cancer cell lines with without EGFR mutation from malignant pleural effusion.

NCT00752076 NSCLC
MeSH:Pleural Effusion, Malignant Pleural Effusion
HPO:Pleural effusion

1 Interventions

Name: cancer cell lines establishment

Description: Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
Type: Other
Group Labels: 1


Primary Outcomes

Measure: EGFR mutation in malignant pleural effusion of lung cancer patients cancer cell lines establishment

Time: 1 year

Purpose: Basic Science

Allocation: N/A

Single Group Assignment

There is one SNP


1 L858R

In-frame deletions in exon 19 centered on codons 756 to 750 make up 45~50% of mutations, and another 35~45% consist of the missense mutation leucine to arginine at codon 858 (L858R) in exon 21 (8, 9, 10). --- L858R ---

It is interesting that exon 19 deletion have increased response and survival with TKIs compared with L858R cases (10, 13, 14). --- L858R ---

This is in contrast to the natural history of patients, where those with exon 19 deletions appear to have shorter survival than those with L858R (8). --- L858R ---

HPO Nodes